HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation

Lung Cancer

Volumn 87, Issue 1, 2015, Pages 14-22

  Suzuki, Mikiko ^a,c   Shiraishi, Kouya ^b   Yoshida, Akihiko ^a   Shimada, Yoko ^b   Suzuki, Kenji ^c   Asamura, Hisao ^a   Furuta, Koh ^a   Kohno, Takashi ^b   Tsuta, Koji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; HER2 amplification; HER2 mutation; HER2 phosphorylation; HER2 protein expression; Lung

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOMATOID CARCINOMA; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR VOLUME; CANCER STAGING; FOLLOW UP; GENE EXPRESSION; GENE REARRANGEMENT; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHOSPHORYLATION; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RISK FACTORS; TUMOR BURDEN; YOUNG ADULT;

EID: 84922262212     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.10.014     Document Type: Article

References (42)

1. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012, 9:16-32.
2. Lorenzen S., Lordick F. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer. Curr Opin Oncol 2011, 23:396-402.
3. Au N.H., Cheang M., Huntsman D.G., Yorida E., Coldman A., Elliott W.M., et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004, 204:101-109.
4. Heinmoller P., Gross C., Beyser K., Schmidtgen C., Maass G., Pedrocchi M., et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003, 9:5238-5243.
5. Stephens P., Hunter C., Bignell G., Edkins S., Davies H., Teague J., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431:525-526.
6. Buttitta F., Barassi F., Fresu G., Felicioni L., Chella A., Paolizzi D., et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006, 119:2586-2591.
7. Pellegrini C., Falleni M., Marchetti A., Cassani B., Miozzo M., Buttitta F., et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003, 9:3645-3652.
8. Rouquette I., Lauwers-Cances V., Allera C., Brouchet L., Milia J., Nicaise Y., et al. Characteristics of lung cancer in women: importance of hormonal and growth factors. Lung Cancer 2012, 76:280-285.
9. Langer C.J., Stephenson P., Thor A., Vangel M., Johnson D.H. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004, 22:1180-1187. Eastern Cooperative Oncology Group Study.
10. Mazieres J., Peters S., Lepage B., Cortot A.B., Barlesi F., Beau-Faller M., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013, 31:1997-2003.
11. Arcila M.E., Chaft J.E., Nafa K., Roy-Chowdhuri S., Lau C., Zaidinski M., et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012, 18:4910-4918.
12. Li C., Sun Y., Fang R., Han X., Luo X., Wang R., et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol 2012, 7:85-89.
13. Tomizawa K., Suda K., Onozato R., Kosaka T., Endoh H., Sekido Y., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 2011, 74:139-144.
14. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005, 65:1642-1646.
15. Yokoyama T., Kondo M., Goto Y., Fukui T., Yoshioka H., Yokoi K., et al. EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 2006, 97:753-759.
16. Sonobe M., Manabe T., Wada H., Tanaka F. Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. J Mol Diagn 2006, 8:351-356.
17. Takahashi T., Sonobe M., Kobayashi M., Yoshizawa A., Menju T., Nakayama E., et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010, 17:889-897.
18. Zhang Y., Sun Y., Pan Y., Li C., Shen L., Li Y., et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 2012, 18:1947-1953.
19. Cardarella S., Ortiz T.M., Joshi V.A., Butaney M., Jackman D.M., Kwiatkowski D.J., et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 2012, 7:1767-1774.
20. Li C., Fang R., Sun Y., Han X., Li F., Gao B., et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011, 6:e28204.
21. Wang S.E., Narasanna A., Perez-Torres M., Xiang B., Wu F.Y., Yang S., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10:25-38.
22. Perera S.A., Li D., Shimamura T., Raso M.G., Ji H., Chen L., et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 2009, 106:474-479.
23. Shimamura T., Ji H., Minami Y., Thomas R.K., Lowell A.M., Shah K., et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006, 66:6487-6491.
24. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
25. Sasaki H., Shimizu S., Endo K., Takada M., Kawahara M., Tanaka H., et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006, 118:180-184.
26. Blons H., Cote J.F., Le Corre D., Riquet M., Fabre-Guilevin E., Laurent-Puig P., et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol 2006, 30:1309-1315.
27. Cappuzzo F., Ligorio C., Janne P.A., Toschi L., Rossi E., Trisolini R., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007, 25:2248-2255.
28. Jin G., Kim M.J., Jeon H.S., Choi J.E., Kim D.S., Lee E.B., et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010, 69:279-283.
29. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
30. Goldstraw P. International association for the study of lung cancer staging manual in thoracic oncology 2009.
31. Travis W.D., Colby T., Corrin B., et al. Tumors of the lung. WHO classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, 9-124. IARC Press. P. Kleihues, L.H. Sobin (Eds.).
32. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
33. Willmore-Payne C., Holden J.A., Layfield L.J. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol 2006, 37:755-763.
34. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
35. Shibata T., Kokubu A., Tsuta K., Hirohashi S. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 2009, 283:203-211.
36. Sun M., Behrens C., Feng L., Ozburn N., Tang X., Yin G., et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009, 15:4829-4837.
37. Lee J.W., Soung Y.H., Kim S.Y., Nam S.W., Park W.S., Wang Y.P., et al. ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett 2006, 237:89-94.
38. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
39. Liu L., Shao X., Gao W., Bai J., Wang R., Huang P., et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010, 5:1922-1932.
40. Frogne T., Laenkholm A.V., Lyng M.B., Henriksen K.L., Lykkesfeldt A.E. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 2009, 11:R11.
41. Tsuta K., Kawago M., Inoue E., Yoshida A., Takahashi F., Sakurai H., et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013, 81:371-376.
42. Broet P., Dalmasso C., Tan E.H., Alifano M., Zhang S., Wu J., et al. Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res 2011, 17:3542-3550.